AAAAAA
Results: 1-25/26
Authors:
Lohrisch, C
Di Leo, A
Piccart, MJ
Citation: C. Lohrisch et al., Optimal adjuvant cytotoxic therapy for breast cancer, BREAST, 10, 2001, pp. 106-113
Authors:
Lohrisch, C
Piccart, MJ
Citation: C. Lohrisch et Mj. Piccart, Standard medical treatment for early breast cancer, EUR J CANC, 37, 2001, pp. S45-S58
Authors:
Piccart, MJ
Lamb, H
Vermorken, JB
Citation: Mj. Piccart et al., Current and future potential roles of the platinum drugs in the treatment of ovarian cancer, ANN ONCOL, 12(9), 2001, pp. 1195-1203
Authors:
Skovsgaard, T
Davidson, NGP
Piccart, MJ
Richel, DJ
Bonneterre, J
Cirkel, DT
Barton, CM
Knight, S
Citation: T. Skovsgaard et al., A phase II study of oral eniluracil/fluorouracil in patients with anthracycline-refractory or anthracycline- and taxane-refractory advanced breast cancer, ANN ONCOL, 12(9), 2001, pp. 1255-1257
Authors:
Di Leo, A
Larsimont, D
Gancberg, D
Jarvinen, T
Beauduin, M
Vindevoghel, A
Michel, J
Focan, C
Ries, F
Gobert, P
Closon-Dejardin, MT
Dolci, S
Rouas, G
Paesmans, M
Lobelle, JP
Isola, J
Piccart, MJ
Citation: A. Di Leo et al., HER-2 and topo-isomerase II alpha as predictive markers in a population ofnode-positive breast cancer patients randomly treated with adjuvant CMF orepirubicin plus cyclophosphamide, ANN ONCOL, 12(8), 2001, pp. 1081-1089
Authors:
Piccart, MJ
Citation: Mj. Piccart, Proposed treatment guidelines for HER2-positive metastatic breast cancer in Europe, ANN ONCOL, 12, 2001, pp. 89-94
Authors:
Piccart, MJ
Di Leo, A
Beauduin, M
Vindevoghel, A
Michel, J
Focan, C
Tagnon, A
Ries, F
Gobert, P
Finet, C
Closon-Dejardin, MT
Dufrane, JP
Kerger, J
Liebens, F
Beauvois, S
Bartholomeus, S
Dolci, S
Lobelle, JP
Paesmans, M
Nogaret, JM
Citation: Mj. Piccart et al., Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer, J CL ONCOL, 19(12), 2001, pp. 3103-3110
Authors:
Cardoso, F
Ferreira, AF
Crown, J
Dolci, S
Paesmans, M
Riva, A
Di Leo, A
Piccart, MJ
Citation: F. Cardoso et al., Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicinin the adjuvant treatment of node positive breast cancer: Results of a feasibility study, ANTICANC R, 21(1B), 2001, pp. 789-795
Authors:
Piccart, MJ
Bertelsen, K
James, K
Cassidy, J
Mangioni, C
Simonsen, E
Stuart, G
Kaye, S
Vergote, I
Blom, R
Grimshaw, R
Atkinson, RJ
Swenerton, KD
Trope, C
Nardi, M
Kaern, J
Tumolo, S
Timmers, P
Roy, JA
Lhoas, F
Lindvall, B
Bacon, M
Birt, A
Andersen, JE
Zee, B
Paul, J
Baron, B
Pecorelli, S
Citation: Mj. Piccart et al., Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results, J NAT CANC, 92(9), 2000, pp. 699-708
Authors:
Piccart, MJ
Citation: Mj. Piccart, Re: Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results - Response, J NAT CANC, 92(17), 2000, pp. 1446-1447
Authors:
Piccart, MJ
Di Leo, A
Hamilton, A
Citation: Mj. Piccart et al., HER2: a 'predictive factor' ready to use in the daily management of breastcancer patients?, EUR J CANC, 36(14), 2000, pp. 1755-1761
Authors:
Piccart, MJ
Du Bois, A
Gore, ME
Neijt, JP
Pecorelli, S
Pujade-Lauraine, E
Citation: Mj. Piccart et al., A new standard of care for treatment of ovarian cancer, EUR J CANC, 36(1), 2000, pp. 10-12
Authors:
Gianni, AM
Piccart, MJ
Citation: Am. Gianni et Mj. Piccart, Optimising chemotherapy dose density and dose intensity: new strategies toimprove outcomes in adjuvant therapy for breast cancer - Introduction, EUR J CANC, 36, 2000, pp. S1-S3
Authors:
Piccart, MJ
Biganzoli, L
Di Leo, A
Citation: Mj. Piccart et al., The impact of chemotherapy dose density and dose intensity on breast cancer outcome: what have we learned?, EUR J CANC, 36, 2000, pp. S4-S10
Authors:
Di Leo, A
Crown, J
Nogaret, JM
Duffy, K
Bartholomeus, S
Dolci, S
Rowan, S
O'Higgins, N
Paesmans, M
Larsimont, D
Riva, A
Piccart, MJ
Citation: A. Di Leo et al., A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer, ANN ONCOL, 11(2), 2000, pp. 169-175
Authors:
Piccart, MJ
Green, JA
Lacave, AJ
Reed, N
Vergote, I
Benedetti-Panici, P
Bonetti, A
Kristeller-Tome, V
Fernandez, CM
Curran, D
Van Glabbeke, M
Lacombe, D
Pinel, MC
Pecorelli, S
Citation: Mj. Piccart et al., Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group, J CL ONCOL, 18(6), 2000, pp. 1193-1202
Authors:
Piccart, MJ
Awada, A
Citation: Mj. Piccart et A. Awada, State-of-the-art chemotherapy for advanced breast cancer, SEMIN ONCOL, 27(5), 2000, pp. 3-12
Authors:
Cornez, N
Piccart, MJ
Citation: N. Cornez et Mj. Piccart, Breast cancer and Herceptin, B CANCER, 87(11), 2000, pp. 847-858
Authors:
Awada, A
Di Leo, A
Piccart, MJ
Citation: A. Awada et al., News on the treatment of breast cancer, B CANCER, 87(1), 2000, pp. 49-62
Authors:
Tanner, M
Gancberg, D
Di Leo, A
Larsimont, D
Rouas, G
Piccart, MJ
Isola, J
Citation: M. Tanner et al., Chromogenic in situ hybridization - A practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples, AM J PATH, 157(5), 2000, pp. 1467-1472
Authors:
Rustin, GJS
Nelstrop, AE
Bentzen, SM
Piccart, MJ
Bertelsen, K
Citation: Gjs. Rustin et al., Use of tumour markers in monitoring the course of ovarian cancer, ANN ONCOL, 10, 1999, pp. 21-27
Authors:
Piccart, MJ
Stuart, GCE
Cassidy, J
Bertelsen, K
Parmar, MKB
Eisenhauer, EA
Kaye, SB
Trope, C
Swenerton, K
Harper, P
Vermorken, JB
Citation: Mj. Piccart et al., Intergroup collaboration in ovarian cancer: a giant step forward, ANN ONCOL, 10, 1999, pp. 83-86
Authors:
Piccart, MJ
McGuire, WP
Citation: Mj. Piccart et Wp. Mcguire, ICON2 trial, LANCET, 353(9152), 1999, pp. 587-587
Authors:
Di Leo, A
Piccart, MJ
Citation: A. Di Leo et Mj. Piccart, Paclitaxel activity, dose, and schedule: Data from phase III trials in metastatic breast cancer, SEMIN ONCOL, 26(3), 1999, pp. 27-32
Authors:
Vermorken, JB
Huinink, WWT
Kobierska, A
van der Burg, MEL
Forni, M
Piccart, MJ
van der Putten, E
Citation: Jb. Vermorken et al., Phase I study of high-dose epirubicin in platinum-pretreated patients withovarian carcinoma, ONCOL-BASEL, 57(1), 1999, pp. 10-16